Alvarez-Cienfuegos Ana, Nuñez-Prado Natalia, Compte Marta, Cuesta Angel M, Blanco-Toribio Ana, Harwood Seandean Lykke, Villate Maider, Merino Nekane, Bonet Jaume, Navarro Rocio, Muñoz-Briones Clara, Sørensen Karen Marie Juul, Mølgaard Kasper, Oliva Baldo, Sanz Laura, Blanco Francisco J, Alvarez-Vallina Luis
Department of Antibody Engineering, Leadartis SL, Ferraz 3, 28008 Madrid, Spain.
Molecular Immunology Unit, Hospital Universitario Puerta de Hierro Majadahonda, Manuel de Falla 1, 28222 Madrid, Spain.
Sci Rep. 2016 Jun 27;6:28643. doi: 10.1038/srep28643.
Here, we describe a new strategy that allows the rapid and efficient engineering of mono and multispecific trivalent antibodies. By fusing single-domain antibodies from camelid heavy-chain-only immunoglobulins (VHHs) to the N-terminus of a human collagen XVIII trimerization domain (TIE(XVIII)) we produced monospecific trimerbodies that were efficiently secreted as soluble functional proteins by mammalian cells. The purified VHH-TIE(XVIII) trimerbodies were trimeric in solution and exhibited excellent antigen binding capacity. Furthermore, by connecting with two additional glycine-serine-based linkers three VHH-TIE(XVIII) modules on a single polypeptide chain, we present an approach for the rational design of multispecific tandem trimerbodies with defined stoichiometry and controlled orientation. Using this technology we report here the construction and characterization of a tandem VHH-based trimerbody capable of simultaneously binding to three different antigens: carcinoembryonic antigen (CEA), epidermal growth factor receptor (EGFR) and green fluorescence protein (GFP). Multispecific tandem VHH-based trimerbodies were well expressed in mammalian cells, had good biophysical properties and were capable of simultaneously binding their targeted antigens. Importantly, these antibodies were very effective in inhibiting the proliferation of human epidermoid carcinoma A431 cells. Multispecific VHH-based trimerbodies are therefore ideal candidates for future applications in various therapeutic areas.
在此,我们描述了一种新策略,该策略可实现单价和多特异性三价抗体的快速高效工程化。通过将来自骆驼科仅重链免疫球蛋白的单域抗体(VHH)融合到人胶原蛋白XVIII三聚化结构域(TIE(XVIII))的N端,我们制备了单价三聚体抗体,其作为可溶性功能蛋白被哺乳动物细胞有效分泌。纯化后的VHH-TIE(XVIII)三聚体抗体在溶液中呈三聚体形式,并表现出优异的抗原结合能力。此外,通过在单条多肽链上用两个额外的基于甘氨酸 - 丝氨酸的接头连接三个VHH-TIE(XVIII)模块,我们提出了一种合理设计具有确定化学计量和可控取向的多特异性串联三聚体抗体的方法。利用该技术,我们在此报告了一种基于VHH的串联三聚体抗体的构建与表征,该抗体能够同时结合三种不同抗原:癌胚抗原(CEA)、表皮生长因子受体(EGFR)和绿色荧光蛋白(GFP)。基于VHH的多特异性串联三聚体抗体在哺乳动物细胞中表达良好,具有良好的生物物理性质,并且能够同时结合其靶向抗原。重要的是,这些抗体在抑制人表皮样癌A431细胞增殖方面非常有效。因此,基于VHH的多特异性三聚体抗体是未来在各种治疗领域应用的理想候选物。